Minimizing Toxicity through Multidisciplinary Care of Complex Head and Neck Cancer Cases - AM2019
In this course, through complex head and neck case examples, a multidisciplinary panel will discuss the relative merits of primary chemoradiation approaches and/or surgical approaches for locally advanced head and neck cancer in the context of optimizing cure, while considering organ preservation, and acute and long term toxicity management. Participants will understand the rationale of various sequencing options of multimodality therapy using specific case examples and understand the risks and potential long term outcomes based on treatment selection. Case examples will be presented in a multidisciplinary discussion and with focused teaching points and, will include the management of:
- Locally advanced oropharyngeal cancer
- Locally advanced paranasal sinus cancer
- Locally advanced oral cavity cancer
- Locally advanced laryngeal cancer
- High grade salivary cancer
The meeting is designed to meet the interests of radiation oncologists, medical oncologists, surgeons, and residents.
- Discuss the relative merits with respect to appropriate patient selection of primary chemoradiation approaches versus surgery in locally advanced head and neck cancer.
- Differentiate which disease sites will benefit from upfront surgical approaches versus chemoradiation approaches in terms of long term toxicity.
The following persons served as faculty for this activity:
Christina Chapman, MD, MS is employed at University of Michigan and has nothing to disclose.
Roi Dagan, MD,MS is employed at University of Florida College of Medicine and receives compensation/remuneration/funding from Electa.
Jill Gilbert, MD, is employed at Vanderbilt University Medical Center and receives compensation/remuneration/funding from Amgen, Astra Zeneca, Bayer, Cue Pharmaceuticals, Merck, Pfizer, and Up to Date.
Minh Tam Truong, MD, MBBS is employed at Boston Medical Center and has nothing to disclose.
Sue Yom, MD, PhD is employed at University of California and receives compensation/remuneration/funding from BioMimetix, Bristol-Myers Squibb, Galera, Genentech, Merck, Springer, and Up to Date.
Jose Zevallos, MD is employed by Washington University in St Louis and receives compensation/remuneration/funding from Nanobiotix.
Additionally, the Education and CME/MOC Committee had control over the content of this activity.
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing education to physicians.
ASTRO is awarded Deemed Status by the American Board of Radiology to provide SA-CME as part of Part II Maintenance of Certification.
- 1.00 Certificate of AttendanceThis activity was designated for 1.00 AMA PRA Category 1 Credit™.
- 1.00 SA-CME
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing medical education for physicians.
The American Society for Radiation Oncology (ASTRO) designates this Enduring material for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity meets the American Board of Radiology's criteria for a self-assessment activity in the ABR's Maintenance of Certification program. Participation in this course in combination with the successful completion of the corresponding assessment and course evaluation adheres to the guidelines established by the ABR for 1.00 self-assessment credits.
- No refunds, extensions or substitutions will be made for those registrants who, for any reason, were unable to attend or were tardy for the session.
- No credits will be granted and no refunds, exchanges or transfers will be given to those who do not pass.
- ASTRO staff cannot make modifications to your submitted materials.
One of the two latest versions of Google Chrome, Mozilla Firefox, Internet Explorer or Safari.